ConductScience.org, home

Paper7779709

In vitro anthracycline cross-resistance pattern in childhood acute lymphoblastic leukaemia.

Klumper E and 5 others. Br J Cancer, 1995. Cited by 21 papers, by iCite.

Cite this record

ConductScience Library. In vitro anthracycline cross-resistance pattern in childhood acute lymphoblastic leukaemia. Papers, record 7779709. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/7779709

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
In vitro anthracycline cross-resistance pattern in childhood acute lymphoblastic leukaemia.
PubMed
Journal
Br J Cancer
PubMed
Year
1995
PubMed
Publication types
Comparative Study, Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
21
iCite
Relative citation ratio, by iCite
0.65
iCite
Revised in PubMed
2019-05-15
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Klumper EE
2Pieters RR
3den Boer MLM L
4Huismans DRD R
5Loonen AHA H
6Veerman AJA J

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibiotics, AntineoplasticMajor topic
Bone MarrowMajor topic
Precursor Cell Lymphoblastic Leukemia-LymphomaMajor topic
Aclarubicin
Child
Daunorubicin
Dose-Response Relationship, Drug
Drug Resistance
Humans
Idarubicin
Mitoxantrone
Recurrence

Source PubMed

Download CSV of topics

References36

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
16952961Phase I trial of aclacinomycin A.Cancer Treat Rep1982https://conductscience.org/library/papers/6952961PubMed
21678081Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia.Lancet1991https://conductscience.org/library/papers/1678081PubMed
33858013Identification of anthracycline analogues with enhanced cytotoxicity and lack of cross-resistance to adriamycin using a series of mammalian cell lines in vitro.Cancer Chemother Pharmacol1985https://conductscience.org/library/papers/3858013PubMed
44019122Mitoxantrone in refractory acute leukemia in children: a phase I study.Invest New Drugs1985https://conductscience.org/library/papers/4019122PubMed
53516918Idarubicin (4-demethoxydaunorubicin). A preliminary overview of preclinical and clinical studies.Invest New Drugs1986https://conductscience.org/library/papers/3516918PubMed
637188179-alkyl anthracyclines. Absence of cross-resistance to adriamycin in human and murine cell cultures.Br J Cancer1986https://conductscience.org/library/papers/3718817PubMed
73757156Pharmacokinetics of mitoxantrone in humans following single-agent infusion or intra-arterial injection therapy or combined-agent infusion therapy.Cancer Chemother Pharmacol1986https://conductscience.org/library/papers/3757156PubMed
83471321Phase I and clinical pharmacological study of 4-demethoxydaunorubicin (idarubicin) in children with advanced cancer.Cancer Res1987https://conductscience.org/library/papers/3471321PubMed
93476202Phase II study of idarubicin administered i.v. to pediatric patients with acute lymphoblastic leukemia.Cancer Treat Rep1987https://conductscience.org/library/papers/3476202PubMed
103305216Aggressive combination chemotherapy of bone marrow relapse in childhood acute lymphoblastic leukemia containing aclacinomycin-A: a multicentric trial.Haematol Blood Transfus1987https://conductscience.org/library/papers/3305216PubMed
113480081Cellular and plasma adriamycin concentrations in long-term infusion therapy of leukemia patients.Cancer Chemother Pharmacol1987https://conductscience.org/library/papers/3480081PubMed
123165708Phase I clinical trial of orally administered 4-demethoxydaunorubicin (idarubicin) with pharmacokinetic and in vitro drug sensitivity testing in children with refractory leukemia.Cancer Res1988https://conductscience.org/library/papers/3165708PubMed
133207599Cross resistance pattern towards anticancer drugs of a human carcinoma multidrug-resistant cell line.Br J Cancer1988https://conductscience.org/library/papers/3207599PubMed
143062256[Antineoplastic effectiveness and toxicity of idarubicin (4-demethoxy-daunorubicin) in recurrent acute leukemias in childhood].Klin Padiatr1988https://conductscience.org/library/papers/3062256PubMed
152924371Comparative effectiveness of mitoxantrone and doxorubicin in overcoming experimentally induced drug resistance in murine and human tumour cell lines in vitro.Cancer Chemother Pharmacol1989https://conductscience.org/library/papers/2924371PubMed
162547527
Identification of anthracyclines and related agents that retain preferential activity over adriamycin in multidrug-resistant cell lines, and further resistance modification by verapamil and cyclosporin A.
Cancer Chemother Pharmacol1989https://conductscience.org/library/papers/2547527PubMed
172576650Failure to detect the P-glycoprotein multidrug resistant phenotype in cases of resistant childhood acute lymphocytic leukaemia.Eur J Cancer Clin Oncol1989https://conductscience.org/library/papers/2576650PubMed
182208112Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Childrens Cancer Study Group report.Cancer Res1990https://conductscience.org/library/papers/2208112PubMed
192257305In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions.Blood1990https://conductscience.org/library/papers/2257305PubMed
201878583Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM group.Blood1991https://conductscience.org/library/papers/1878583PubMed

See all 36 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 21 citations.

PMIDTitleJournalYearIn PapersSource
41310667Targeting the MAGED2-TRIM28-FLNC axis overcomes chemoresistance in TNBC via EMT suppression.Cell Commun Signal2025https://conductscience.org/library/papers/41310667PubMed
27632202Improvement of the Outcome of Relapsed or Refractory Acute Lymphoblastic Leukemia in Children Using a Risk-Based Treatment Strategy.PLoS One2016https://conductscience.org/library/papers/27632202PubMed
25295084Salvage therapy with mitoxantrone, etoposide, bleomycin and dexamethasone for refractory or relapsed aggressive non-Hodgkin's lymphoma patients with a poor performance status or comorbidity.Oncol Lett2014https://conductscience.org/library/papers/25295084PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/7779709

GET https://conductscience.org/api/papers/v1/7779709/references?page=2